Cytosorbents (NASDAQ:CTSO) Receives “Neutral” Rating from HC Wainwright

HC Wainwright restated their neutral rating on shares of Cytosorbents (NASDAQ:CTSO) in a report issued on Tuesday, Benzinga reports. The brokerage currently has a $1.00 target price on the medical research company’s stock.

Separately, StockNews.com assumed coverage on shares of Cytosorbents in a report on Thursday, May 2nd. They issued a hold rating for the company.

Cytosorbents Stock Performance

Shares of Cytosorbents stock opened at $0.93 on Tuesday. The firm has a 50-day simple moving average of $0.91 and a two-hundred day simple moving average of $1.12. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.51 and a current ratio of 1.77. Cytosorbents has a fifty-two week low of $0.78 and a fifty-two week high of $4.29. The company has a market cap of $50.63 million, a P/E ratio of -1.46 and a beta of 0.62.

Cytosorbents (NASDAQ:CTSO) last released its quarterly earnings results on Thursday, March 14th. The medical research company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.02. Cytosorbents had a negative return on equity of 120.24% and a negative net margin of 78.43%. The company had revenue of $8.67 million during the quarter, compared to analysts’ expectations of $9.29 million. As a group, equities analysts predict that Cytosorbents will post -0.36 earnings per share for the current fiscal year.

Institutional Trading of Cytosorbents

Several institutional investors have recently modified their holdings of the stock. Key Client Fiduciary Advisors LLC grew its position in shares of Cytosorbents by 188.0% in the first quarter. Key Client Fiduciary Advisors LLC now owns 34,557 shares of the medical research company’s stock valued at $33,000 after purchasing an additional 22,557 shares during the period. Avenir Corp lifted its stake in shares of Cytosorbents by 12.3% in the fourth quarter. Avenir Corp now owns 3,051,402 shares of the medical research company’s stock worth $3,387,000 after buying an additional 334,005 shares in the last quarter. Neuberger Berman Group LLC lifted its stake in shares of Cytosorbents by 19.9% in the fourth quarter. Neuberger Berman Group LLC now owns 1,801,799 shares of the medical research company’s stock worth $1,997,000 after buying an additional 299,103 shares in the last quarter. Skylands Capital LLC lifted its stake in shares of Cytosorbents by 10.5% in the fourth quarter. Skylands Capital LLC now owns 3,254,213 shares of the medical research company’s stock worth $3,612,000 after buying an additional 309,543 shares in the last quarter. Finally, Sargent Investment Group LLC lifted its stake in shares of Cytosorbents by 4.1% in the fourth quarter. Sargent Investment Group LLC now owns 1,308,747 shares of the medical research company’s stock worth $1,453,000 after buying an additional 51,699 shares in the last quarter. Institutional investors and hedge funds own 32.87% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.